Theodore E. Hebert

Array ( [id] => 11009764 [patent_doc_number] => 20160206717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'STIMULATION OF IMMUNITY TO ENDOTHELIAL CELLS, ENDOTHELIAL-LIKE CELLS, AND INTRATUMOR VASCULAR CHANNELS DERIVED FROM TUMOR TISSUE' [patent_app_type] => utility [patent_app_number] => 15/001161 [patent_app_country] => US [patent_app_date] => 2016-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14699 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15001161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16367844 [patent_doc_number] => 10799579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Methods for enhancing antigen-specific immune responses [patent_app_type] => utility [patent_app_number] => 15/543806 [patent_app_country] => US [patent_app_date] => 2016-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 31743 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15543806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11269202 [patent_doc_number] => 20160331750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'METHODS FOR TREATMENT OF LYMPHOMAS WITH MUTATIONS IN CELL CYCLE GENES' [patent_app_type] => utility [patent_app_number] => 14/990577 [patent_app_country] => US [patent_app_date] => 2016-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 12503 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14990577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10763299 [patent_doc_number] => 20160109454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'DISEASE-ASSOCIATED ANTIGENS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/977359 [patent_app_country] => US [patent_app_date] => 2015-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 65812 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14977359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10760553 [patent_doc_number] => 20160106706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'METHOD OF DELIVERING AN ANTI-CANCER AGENT TO A CELL' [patent_app_type] => utility [patent_app_number] => 14/977480 [patent_app_country] => US [patent_app_date] => 2015-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9050 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14977480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10981686 [patent_doc_number] => 20160178630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'METHODS FOR PREDICTING OVERALL SURVIVAL OF CANCER PATIENTS BASED ON NUMBERS OF CIRCULATING TUMOR CELLS' [patent_app_type] => utility [patent_app_number] => 14/974889 [patent_app_country] => US [patent_app_date] => 2015-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 7398 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14974889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092787 [patent_doc_number] => 20170349880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/536258 [patent_app_country] => US [patent_app_date] => 2015-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 12325 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15536258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14425207 [patent_doc_number] => 10317402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Identification, selection and use of high curative potential T cell epitopes [patent_app_type] => utility [patent_app_number] => 14/958780 [patent_app_country] => US [patent_app_date] => 2015-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 23890 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14958780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11736063 [patent_doc_number] => 09700634 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-11 [patent_title] => 'Immunoconjugates with an intracellularly-cleavable linkage' [patent_app_type] => utility [patent_app_number] => 14/956769 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 28049 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14956769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10744272 [patent_doc_number] => 20160090423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity' [patent_app_type] => utility [patent_app_number] => 14/955469 [patent_app_country] => US [patent_app_date] => 2015-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 62558 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14955469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13578775 [patent_doc_number] => 20180340936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => USE OF ED-B PROTEIN IN DIAGNOSIS OF TISSUE HYPERPLASIA [patent_app_type] => utility [patent_app_number] => 15/776395 [patent_app_country] => US [patent_app_date] => 2015-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11090764 [patent_doc_number] => 20160287732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'TUMOR THERAPY BY BISPECIFIC ANTIBODY PRETARGETING' [patent_app_type] => utility [patent_app_number] => 14/942315 [patent_app_country] => US [patent_app_date] => 2015-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 27086 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14942315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10815325 [patent_doc_number] => 20160161485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/930603 [patent_app_country] => US [patent_app_date] => 2015-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 56799 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14930603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11929796 [patent_doc_number] => 09796781 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-24 [patent_title] => 'Markers of acute myeloid leukemia stem cells' [patent_app_type] => utility [patent_app_number] => 14/927349 [patent_app_country] => US [patent_app_date] => 2015-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 36 [patent_no_of_words] => 25704 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14927349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699469 [patent_doc_number] => 20160045616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/924960 [patent_app_country] => US [patent_app_date] => 2015-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 21679 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14924960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685859 [patent_doc_number] => 20160032004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity' [patent_app_type] => utility [patent_app_number] => 14/885174 [patent_app_country] => US [patent_app_date] => 2015-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 65672 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14885174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10755039 [patent_doc_number] => 20160101191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY' [patent_app_type] => utility [patent_app_number] => 14/878556 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16769 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14878556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11853052 [patent_doc_number] => 20170227544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'METHODS FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST' [patent_app_type] => utility [patent_app_number] => 15/502339 [patent_app_country] => US [patent_app_date] => 2015-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15388 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15502339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17420139 [patent_doc_number] => 11253568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response [patent_app_type] => utility [patent_app_number] => 15/515033 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 13180 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15515033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648790 [patent_doc_number] => 10925944 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Cell population for use in treating cancer [patent_app_type] => utility [patent_app_number] => 15/510222 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 8662 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15510222 [rel_patent_id] =>[rel_patent_doc_number] =>)